LeMaitre Vascular Inc (LMAT)

Man Group plc recently acquired 29,417 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) for approximately $2.82 million, establishing a 0.13% stake in the medical instruments supplier. The stock currently has a "Hold" consensus rating from analysts with an average target price of $110.60, despite the company missing its latest quarterly earnings and revenue expectations. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.

Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 in Q2 2026 due to a speculative rally favoring high-beta stocks, which negatively impacted their quality-focused approach and healthcare holdings like LeMaitre Vascular (LMAT). Despite LMAT's 12% decline in the quarter, Riverwater Partners maintains that the company's fundamental strengths, including niche leadership and consistent execution, remain intact, viewing the weakness as sentiment-driven. While acknowledging LMAT's potential, the firm is also exploring AI stocks with greater upside and less downside risk.

Bank of New York Mellon Corp has acquired a new stake of $16.55 million in LeMaitre Vascular, Inc., purchasing 172,458 shares. This investment means institutional investors now collectively own 84.64% of LMAT, despite the company recently missing quarterly earnings estimates and receiving a mixed "Hold" consensus rating from analysts. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.

Deutsche Bank AG has acquired 24,080 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $2.31 million. Despite this investment and significant institutional ownership, several analysts have recently downgraded the stock to "Hold" due to missed earnings and revenue expectations. The company also declared a quarterly dividend of $0.25 per share.

Grandeur Peak Global Advisors LLC has acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT), purchasing 161,010 shares valued at approximately $15.45 million, making it their ninth-largest holding. This investment comes as LeMaitre Vascular reported quarterly earnings that missed analyst expectations, with an EPS of $0.74 against an anticipated $0.81 and revenue of $70.38 million compared to $71.47 million expected. Despite the earnings miss, the company announced a quarterly dividend of $0.25, contributing to a 1.3% annualized yield, while analysts maintain a consensus "Hold" rating with an average price target of $110.60.